Menu Back toNovel-Approaches-for-Accessing-the-CNS-Nonclinical-and-Clinical-Challenges

DIA 2018 Global Annual Meeting


Novel Approaches for Accessing the CNS: Nonclinical and Clinical Challenges

    Session Chair(s)
      Richard  Scheyer, MD

      Richard Scheyer, MD

      • Vice President, Medical Affairs
      • Medpace, United States
    This session will highlight new approaches in CNS-targeted therapeutics. These approaches to address specific genetic perturbations, pioneered in rare disease, require new approaches to study designs and execution.
    Learning Objective : Design studies for advanced treatment modalities, with focus on CNS therapeutics; Describe associated hurdles in pre-clinical evaluation, patient identification, treatment, assessment, and follow-up.
    Speaker(s)
      Richard  Scheyer, MD

      Novel Approaches to Confirming CNS Penetration and Target Engagement

      Richard Scheyer, MD

      • Vice President, Medical Affairs
      • Medpace, United States
      Dinah  Duarte, PharmD, MSc

      Nonclinical Models Supporting Orphan Drug Designations in Rare Neurodegenerative Conditions

      Dinah Duarte, PharmD, MSc

      • Scientific Evaluation Unit, Directorate of Medicinal Products
      • INFARMED, Portugal
      William  Elmquist, PharmD, PhD

      Accessing the Brain in the Era of Taergeting Therapeutics

      William Elmquist, PharmD, PhD

      • Distinguished Professor, Department of Pharmaceutics, College of Pharmacy
      • Univerity of Minnesota, United States